Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.

doi:10.1038/s41375-025-02711-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.

Leukemia - 1 Sept 2025

Bazinet Alexandre, Loghavi Sanam, Wei Yue, Bataller Alex, Sasaki Koji, Arani Naszrin, Darbaniyan Faezeh, Chien Kelly, Hammond Danielle, Bouligny Ian, Kanagal-Shamanna Rashmi, Thongon Natthakan, Tang Guilin, Urrutia Samuel, Kadia Tapan, DiNardo Courtney, Daver Naval, Short Nicholas, Issa Ghayas, Pemmaraju Naveen, Jabbour Elias, Wang Sa A, Wang Wei, Borthakur Gautam, Bueso-Ramos Carlos, Ravandi Farhad, Medeiros L Jeffrey, Kantarjian Hagop, Garcia-Manero Guillermo, Montalban-Bravo Guillermo

Abstract excerpt

Erythroid differentiation confers BCL-XL dependence and venetoclax resistance in acute myeloid leukemia (AML). However, whether myelodysplastic neoplasms (MDS) with erythroid predominance (EP), defined by ≥50% erythroid bone marrow elements, have distinct biology and drug sensitivities remains unknown. To study this, we evaluated an MDS patient cohort (n = 371) and showed that EP MDS (n = 67, 18%) are...

Topics

Humans
Sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
Myelodysplastic Syndromes
Male
Female
Aged
Middle Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Aged, 80 and over

Prognosis

Adult

Erythroid Cells

Biomarkers, Tumor

Tumor Suppressor Protein p53

Survival Rate

Genomics

Source

Open in PubMed

Identifiers

PMID: 40691503
DOI: 10.1038/s41375-025-02711-6

Genes

TP53
ASXL1
BCOR
SRSF2
WT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.PMID 40691503Read ↗

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsSemantic proximity Read ↗

TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.Semantic proximity Read ↗

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemiaSemantic proximity Read ↗

Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases.Semantic proximity Read ↗

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapySemantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.Semantic proximity Read ↗

Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased BlastsSemantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapySemantic proximity Read ↗

Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic SyndromesSemantic proximity Read ↗

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.